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Abstract
Background: Cancer Stem Cells (CSCs) hypothesis asserts that only a small subset of cells within a tumour is capable of both
tumour initiation and sustainment. The Epithelial-Mesenchymal Transition (EMT) is an embryonic developmental program
that is often activated during cancer invasion and metastasis. The aim of this study is to shed light on the relationship
between EMT and CSCs by using LC31 lung cancer primary cell line.
Materials and Methods: A549 and LC31 cell lines were treated with 2 ng/ml TGFb-1 for 30 days, and 80 days, respectively.
To evaluate EMT, morphological changes were assessed by light microscopy, immunofluorescence and cytometry for
following markers: cytokeratins, e-cadherin, CD326 (epithelial markers) and CD90, and vimentin (mesenchymal markers).
Moreover, RT-PCR for Slug, Twist and b-catenin genes were performed. On TGFb-1 treated and untreated LC31 cell lines, we
performed stemness tests such as pneumospheres growth and stem markers expression such as Oct4, Nanog, Sox2, c-kit
and CD133. Western Blot for CD133 and tumorigenicity assays using NOD/SCID mice were performed.
Results: TGFb-1 treated LC31 cell line lost its epithelial morphology assuming a fibroblast-like appearance. The same results
were obtained for the A549 cell line (as control). Immunofluorescence and cytometry showed up-regulation of vimentin and
CD90 and down-regulation of cytocheratin, e-cadherin and CD326 in TGFb-1 treated LC31 and A549 cell lines. Slug, Twist
and b-catenin m-RNA transcripts were up-regulated in TGFb-1 treated LC31 cell line confirming EMT. This cell line showed
also over-expression of Oct4, Nanog, Sox2 and CD133, all genes of stemness. In addition, in TGFb-1 treated LC31 cell line, an
increased pneumosphere-forming capacity and tumours-forming ability in NOD/SCID mice were detectable.
Conclusions: The induction of EMT by TGFb-1 exposure, in primary lung cancer cell line results in the acquisition of
mesenchymal profile and in the expression of stem cell markers.
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Introduction
Two important hypothesis have been postulated in the genesis,
formation, growth, and metastasis of epithelial cancer: the role of
Cancer Stem Cells (CSCs) or Tumour Initiating Cells (TICs) and the
involvement of the so called Epithelial-Mesenchymal Transition
(EMT).
Cancerstemcellshavebeendefinedas‘‘acellwithinatumourthat
possess the capacity to self-renew and to cause the heterogeneous
lineages of cancer cells that comprise the tumour’’ [1]. These two
definitive biological properties are what make the CSCs the prime
candidate for initiation of relapse.
CSCs hypothesis asserts that only a small subset of cells within a
tumour is able of both tumour initiation and sustainment [2,3].
These cells express stemness markers, are able to form floating
spheres in serum-free medium, a property associated with stem
cells, and are also able to differentiate in an aberrant cell
phenotype constituting tumour heterogeneity [4]. Experimentally,
this population is identified by its ability to form new tumours
through serial transplantations in immunodeficient non-obese
diabetic (NOD)/severe combined immunodeficient (SCID) mice,
re-establishing tumour heterogeneity [5].
There are two basic topics that underline the hypothesis that
CSCs originate from normal tissue stem cells. First of all, the CSCs
have normal stem cell properties such as self-renewal, differenti-
ation, drug resistance and migration capacity. Then, the longevity
of stem cells make them susceptible to accumulating genetic and
epigenetic damages so as to make them good candidates for the
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only cells that are capable of generating tumours similar to the
original patient specimens when transplanted into immunocom-
promised mice such as NOD/SCID mice [8].
Existing therapies have enhanced the length of survival after
diagnosis of cancer, but completely failed in terms of recovery.
Cancer therapy failures may be due to inefficient effects of current
therapy upon potentially quiescent CSCs, which remain vital and
retain the capacity to regenerate the tumour [9]. In most cases,
current therapeutic strategies are developed to target the bulk of
cancer and likely do not eradicate CSCs completely. CSCs are more
resistant to therapies, due to survival advantage with increased anti-
apoptotic activities and drug resistancedue to increased levelsof drug
efflux pumps such as BCRP (breast cancer resistance protein) and
MDR (multi-drug resistance) complexes [10,11].
The CSCs have been identified in a variety of solid tumours
including glioblastomas [12], breast [13], and lung cancer [14,15].
There are three distinct main methodologies to isolate CSCs from
solid tumours: i) isolation of CSCs by flow cytometry according to
CSC-specific cell surface markers such as CD44 or CD133; ii)
detection of side population phenotype by Hoechst33342
exclusion; iii) the sphere formation under the cultivation of
defined serum-free medium with growth factors which maintains
the CSCs undifferentiated.
The Epithelial-Mesenchymal Transition (EMT) is an embryonic
key developmental program that is often activated during cancer
invasion and metastasis [16,17]. It is a process by which cells
undergo a morphological switch from the epithelial polarized
phenotype to the mesenchymal fibroblastoid phenotype. As a
result of EMT, epithelial cells lose their defined cell–cell/cell–
substratum contacts and their structural/functional polarity, and
they become spindle shaped and morphologically similar to
activated fibroblasts [18]. At the molecular level, EMT is defined
by the loss of cell–cell adhesion molecules (eg, E-cadherin and ZO-
1), down-regulation of epithelial differentiation markers including
cytokeratins and E-cadherin and transcriptional induction of
mesenchymal markers such as vimentin, fibronectin and N-
cadherin with a nuclear localization of beta-catenin [19]. Nuclear
beta-catenin induces a gene expression pattern favouring tumour
invasion, and mounting evidence indicates multiple reciprocal
interactions of E-cadherin and beta-catenin with EMT-inducing
transcriptional repressors to stabilize an invasive mesenchymal
phenotype of epithelial tumour cells [20,21]. Other genes involved
in EMT are Snail, Twist e SIP-1/ZEB-2, all repressors of gene
CDH1 that codes for E-cadherin [16]. Several distinct traits have
been conveyed by EMT, including cell motility, invasiveness,
resistance to apoptosis, and some properties of stem cells. Many
signalling pathways have contributed to the induction of EMT,
including transforming growth factor-beta (TGFb-1), Wnt,
Hedgehog, Notch, and nuclear factor-kappa B (NFkB) [22].
Kyoung-Ok Hong et al. [23] have shown that activation of PI3K/
Akt axis is one of the key mechanisms in the process of EMT and it
seems that its inhibition by treatment with phosphatidylinositol
ether lipid analogues (PIA) may regulate the reverse process
Mesenchymal Epithelial reverse Transition (MErT) leading to the
re-expression of both E-cadherin and b-catenin, and reducing
expression of vimentin, mesenchymal marker, in oral squamous
lines carcinoma stabilized. During the process of tumour
metastasis, which is often enabled by EMTs, disseminated cancer
cells would seem to require self-renewal capability, similar to that
exhibited by stem cells, in order to spread macroscopic metastases
[24]. This raises the possibility that the EMT process, which
enables cancer cell dissemination, may also impart a self-renewal
capability to disseminating cancer cells. Indeed, the metastatic
process is at least superficially similar to the processes that occur
during tissue repair and regeneration and enable adult stem cells
to exit tissue reservoirs such as the bone marrow, enter and survive
in the circulation, and get into secondary tissue sites, where they
proliferate, differentiate, and participate in tissue reconstruction
[25]. Together, these diverse lines of evidence suggest a possible
link between cancer stem cells and the mesenchymal-appearing
cells generated by EMTs and the reverse process termed
Mesenchymal Epithelial reverse Transition (MErT). Mani et
colleagues [26] were the first to demonstrate such correlation in
immortalized human mammary epithelial cells (HMLEs).
In this context, it is important to identify which factors could
induce EMT and how the EMT cells could become a resource for
cancer stem-like cells, developing novel and targeted therapies for
lung cancer. Therefore, the aim of this study is to shed light on the
possible relationship between EMT and CSCs by using LC31
primary cell line obtained from tissue sample after surgery in
patient affected by Non Small Cell Lung Cancer (NSCLC).
Results
TGFb-1 treatment induces morphologic changes in
NSCLC cell lines
In order to investigate the effect of TGFb-1 on LC31 and A549
cell lines, we treated them with 2 ng/ml of TGFb-1. As already
also demonstrated by Ju Hee Kim [27], A549 cells treated with
TGFb-1 lost their epithelial morphology observable after 48 hours
of treatment; they were dispersed and assumed a fibroblast-like
appearance with longed shape and central nucleus.
LC31 cells treated with TGFb-1 lost their epithelial morphology
and acquired mesenchymal traits starting from 21 days of
treatment. The cells became longed, fibroblast like with central
nucleus and started to grow as bundles. This morphology was
maintained for all time of treatment (Fig. 1A–D).
TGFb-1 treatment induces growth inhibition in NSCLC
cell lines
In all cell lines tested, TGFb-1 induced growth inhibition. In
A549, growth curves analyses showed a strong growth inhibition
during culture time with DT 28 h for treated A549 respect to DT
18 h of the corresponding untreated cell line. In LC31 cells, the
DT was 72 h for treated cells whereas DT was 36 h for untreated
cells (Fig. 1E–F).
TGFb-1 treatment promotes a shift from epithelial to
mesenchymal phenotype
The morphological effect of TGFb-1 on A549 and LC31 cell
lines suggested that TGFb-1 promoted an EMT. The morpho-
logical changes characteristic of cells undergoing EMT is
accompanied by a shift in expression from an epithelial to a
mesenchymal repertoire. To determine whether TGFb-1 induced
such shift, we used cytometry, immunofluorescence and RT-PCR
to examine the expression and distribution of CD90, CD326,
vimentin, e-cadherin and cytockeratins markers and b-catenin,
Slug and Twist genes.
According to cytometric analysis, in untreated cell lines, CD90
was weakly expressed on A549 (mean percentage 10%) and LC31
(mean percentage 4%). CD326 and cytokeratins expression levels
were low both in A549 (mean percentage 10% and 1,1%
respectively) and LC31 (mean percentage 1% and 18,6%
respectively). Vimentin was weakly positive in A549 (mean
percentage 22%) and LC31 (mean percentage 17%). After
TGFb-1 treatment, CD90 (mean percentage 93%) and vimentin
EMT in Primary Lung Cancer Cell Line
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cytokeratins decreased in A549 and LC31 (Fig. 2A,B).
In immunofluorescence assay, in the untreated cell lines, vimentin
was expressed both in A549 and LC31 but it was contained in
perinuclear vescicles. Cytokeratins and E-cadherin were weakly
expressed in both cell lines. After TGFb-1 treatment, the vimentin
was strongly and uniformly distributed in all A549 and LC31 cells,
whereas cytokeratins and E-cadherin remained weakly expressed and
localized in perinuclear areas of cells until to be abrogated after 30
days for A549 and 40 days for LC31 (Fig. 3 A–L).
The RT-PCR data showed that there was massive shift of gene
expression from a pattern characteristic of epithelial cells to that of
mesenchymal cells in LC31 cell line with a considerable increase in
the expression of EMT-inducing transcription factors, specifically
beta-catenin (,1,5 fold), Twist (,1,5 fold), and Slug (,2,7 fold)
indicating their EMT phenotype. Up-regulation of these genes
Figure 1. Morphological changes and growth curves after TGF-b1 treatment. A: untreated A549, OM 2006; B: treated A549, at 2 days TGFb-
1 treatment, OM 4006; C: untreated LC31, OM 4006; D: treated LC31, at 30 days TGFb-1 treatment, OM 4006; E: growth curves of untreated and
treated A549; F: growth curves of untreated and treated LC31.
doi:10.1371/journal.pone.0021548.g001
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catenin for which there was an increase at 20 and 80 days of
treatment respect to untreated cell line and a weak decrease at 50
days respect 20 and 80 days of treatment but always increased
respect to untreated cell line (Fig. 3M).
Gene expression profiling of stemness markers in
EMT-LC31 cell line
To investigate the genes regulating and maintaining the stem
cell phenotype of LC31 cells having EMT signatures (termed
EMT-LC31 cell line), we performed RT-PCR for OCT4, Nanog
and Sox2. Interestingly, transcription factors OCT4, Nanog,
Sox2, known to be sufficient to reprogram mouse or human
somatic cells to undifferentiated, pluripotent stem cells, were found
to be significantly increased in EMT-LC31 cell line with an
increase of 3,5 fold, 3,0 fold, and 1,4 fold for OCT4, Nanog and
Sox-2, respectively more than parental cell line indicating their
stemness phenotype (Fig. 4A).
CD133 and c-kit markers were increased in EMT-LC31 cell
line
To further determine whether cells with EMT phenotype could
show cancer stem like cell characteristics, we evaluate expression
of CD133, main marker in identifying cancer stem cells in NSCLC
[14,15] and c-kit [28], mesenchymal stem marker.
Cytometry analyses showed that in LC31 parental cell line, the
percentage of CD133 was 3% of total cell population. After
TGFb-1 treatment, the results showed that no differences in
CD133 expression levels between parental and EMT-cells were
detectable (data not shown). This result is different respect to those
obtained by RT-PCR and western blotting for CD133. Both RT-
PCR and western blotting showed an increase of CD133 (,2,3
fold for RT-PCR) after different times of TGFb-1 treatment.
Regarding c-Kit gene, the latter resulted up-regulated in EMT-
LC31 cells with an increase of ,2,3 fold more than parental cell
line (Fig. 4B,C).
Pneumospheres formation ability was increased in EMT-
LC31 cell line
Liu et al. [29] and others [30] have demonstrated that the
ability to form mammospheres in vitro depends on the presence of
self-renewing. We tested pneumophere-forming ability of EMT-
LC31 cells compared to parental cell line.
Significantly, after we induced an EMT in LC31 cells by exposing
them to TGF-b1, we found that EMT-LC31 cells showed
significantly increased ability to form pneumopheres compared to
parental cell line formingat least .40-foldmorepneumospheresthan
parental cells. The ratio of pneumospheres size and their growth was
significantly greater than those of untreated cells. Moreover, the
EMT pneumospheres were more than 50 mm in diameter after 5
days, while parental pneumospheres were 20 mm( F i g .5 A , B ) .I n
addition all EMT pneumospheres were positive for CD133 (Fig. 5C).
Based on this functional assay, we concluded that the cells generated
by an EMT acquired yet another attribute of lung cancer stem cells.
Colony efficiency analyses
One of the methods of analysing the tumorigenic potential is the
soft agar assay that measures anchorage-independent growth,
which is an indicator for cell transformation. As described in
Table 1, assessment of growth kinetics revealed major colony
efficiency of EMT-LC31 cell line compared to parental cell line
with 18 and 3 fold increase for 1,000 and 10,000, respectively, of
seeded EMT cells respect to parental cell line (Fig. 6A–C).
Figure 2. TGF-b1 up-regulates mesenchymal markers expression and down-regulates epithelial markers expression. A: Cytometric
analysis for CD90, CD326, vimentin and Cytokeratin in untreated (line red) and TGFb-1 treated [line green] in A549 cell line after 20 days of treatment;
B: Cytometric analysis for CD90, CD326, vimentin and Cytokeratin in untreated [line red] and TGFb-1 treated (line green) in LC31 cell line after 30 days
of treatment. Isotype controls are in black.
doi:10.1371/journal.pone.0021548.g002
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corresponding parental cell line
In our previous studies [15], we showed that the tumours from
LC31 cells grown as pneumopsheres grew much faster compared to
that from corresponding cells grown in adherent culture condition.
InordertotestwhetherTGFb-1treatmentsucceeded inalteringthe
tumour-initiating frequency of transformed cells, we injected EMT-
LC31 cells and corresponding cell line into immunodeficient hosts.
As reported in Table S1, we found that the volume of tumour
induced by EMT-LC31 cells was significantly larger than that of
parental cells (Fig. S1). These results suggest that the cells withEMT
signature promoted tumorigenicity in vivo.
Discussion
Epithelial to mesenchymal transition (EMT) is a fundamental
physiologic process whereby epithelial cells lose their polarity and
Figure 3. TGF-b1 promotes EMT. Immunofluorescence for vimentin (A), cytokeratin (B) and e-cadherin (C) on untreated A549 cell line; vimentin
(D), cytokeratin (E) and e-cadherin (F) on treated in A549 cell line after 20 days of TGFb-1 treatment; vimentin (G), cytokeratin (H) and e-cadherin (I) on
untreated LC31 cell line; vimentin (J), cytokeratin (K) and e-cadherin (L) on treated in LC31 cell line after 30 days of TGFb-1 treatment. All
immunofluorescence images have OM 2006; M: RT-PCR analysis and densitometry evaluation for Slug, Twist and b-catenin on untreated and TGFb-1
treated in LC31 cell line after 0, 20, 50 and 80 days of treatment. *, p,0,001, **, p,0,0001 compared to parental cell line (0 day of treatment).
doi:10.1371/journal.pone.0021548.g003
Figure 4. Stemness markers distribution on LC31 and EMT-LC31 cell lines. A: RT-PCR and densitometry evaluation for Oct4, Sox2 and
Nanog genes on LC31 and EMT-LC31 cell lines after 0, 20, 50 and 80 days of treatment; B: RT-PCR and densitometry evaluation for CD133 and c-kit
genes on LC31 and EMT-LC31 cell lines after 0, 20, 50 and 80 days of treatment; C: western blot for CD133 LC31 and EMT-LC31 cell lines after 0, 20, 50
and 80 days of treatment. *, p,0,001, **, p,0,0001 compared to LC31 cell line (0 day of treatment). a-tubulin is used as loading control.
doi:10.1371/journal.pone.0021548.g004
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EMT include loss of cell-cell adhesion, re-organization of the
cytoskeletal actin and acquisition of increased migratory charac-
teristics [31,32].
EMT is a crucial event in tumour progression and several studies
state that the EMT is activated in many types of cancers [33–35].
Despite recent progress, further studies are needed to clarify the role
of EMT in the invasion and metastasis of tumours. During the
process of tumour metastasis, cancer cells, that metastasize, acquire
skills of self-renewal, similar to that exhibited by stem cells in order
to spread the metastases [24].
Together, these evidences suggest a possible link between cancer
stem cells and the mesenchymal-appearing cells generated by EMTs.
In this context, aim of this study is to show that EMT
acquisition is associated with an increase of stemness signatures in
a primary cell line obtained in our laboratory. A549 lung cancer is
a well-characterized cell line that has been used as a model system
to study the mechanisms of carcinogenesis, apoptosis and cancer
progression in lung cancer [36,37]. Because EMT plays a key role
in the tumor progression, we chose A549 cell line as model system
of EMT. We focused our attention on LC31 cell line obtained in
our laboratory and investigate the effect of TGFb-1 on EMT and
stemness mechanism on this line. In agreement with previous
reports [38,39], we showed that TGFb-1 induces EMT in A549
cells by acquisition of mesenchymal morphology, increased
expression of mesenchymal markers such as vimentin and CD90
and decreased expression of epithelial markers such as cytokeratins
and CD326. Once defined that our EMT study model is useable,
we tested the effect of TGFb-1 on LC31 cell line. We treated
LC31 cell line with TGFb-1 2 ng/ml for 80 days. Only after about
20 days, we observe morphological changes that are consistent
with the acquisition of EMT phenotype as characterized by the
loss of expression of epithelial markers such as cytokeratins, e-
cadherin and CD326 and the gain or increased expression of
mesenchymal markers such as vimentin replacing cytokeratins.
After 20 days of treatment, LC31 cells became elongated, central
nucleus with fibroblast like shape and increased stress fiber
reorganization.
EMT takes 48 hours in A549 because it has stronger mesenchymal
markers expression than LC31 needing 20 days to undergo EMT.
Therefore, the LC31 cell line displays several features typical of
EMT: reduction in cell-cell adhesion, flattening and scattering,
expression of mesenchymal markers. Slug, Twist and b-catenin,
main transcriptional factors involved in EMT, are up-regulated in
the cells treated and these factors increase with increasing TGFb-1
treatment time, confirming their EMT phenotype.
These results open the way to verify if LC31 primary lung cancer
cell line, sensitive to TGFb-1 treatment, could increase stem cell
characteristics. Interestingly, EMT-LC31 cells also display stem-
like cell phenotype characterized by increased pneumosphere-
forming capacity compared with parental LC31 cell line with EMT
pneumospheres greater than parental pneumopheres. Moreover
EMT pneumospheres were positive for CD133 marker reinforcing
the stemness signature. Most importantly, it is well known that the
co-expression of Sox-2, Nanog and Oct4 in human or mouse
somatic cells can reprogram these cells into pluripotent embryonic
stem-like cells [40,41]. In our study, we found that the expressions
of Sox-2, Nanog and Oct4 were dramatically up-regulated in
EMT-LC31 cell line compared to parental cell line. Taken together
these data, LC31 cell line with EMT signature showed an increase
of stem-like cell characteristics associated with over-expression of
Sox-2, Nanog and Oct4.
Recent studies have shown that c-kit and its ligand are
expressed in lung cancer. Immunohistological studies on the c-
kit expression showed that the protein is aberrantly expressed only
in lung cancer cells and not in pneumocytes or normal bronchial
epithelial cells [42]. In addition, Levina et al. [43,44] have showed
that the treatment of lung tumour cells with doxorubicin, cisplatin,
or etoposide resulted in the selection of drug surviving cells
expressing CD133, CD117, SSEA-3, TRA1-81, Oct-4, and
nuclear beta-catenin with low expression of the differentiation
markers cytokeratins 8/18. In our study, we demonstrate that
TGFb-1 induces also an increase of c-kit m-RNA expression,
another stemness marker, reinforcing the hypothesis that LC31
cell line with EMT signature showed an increase of stem
phenotype. Another interesting result is the up-regulation of
CD133 in EMT-LC31 cell line, main marker for CSCs
identification in lung cancer as reported by Eramo et al. [14]
and Tirino et al. [15]. In our study, we observed an increase of
CD133 both in RT-PCR and Western blot, but not in cytometry
and immunofluorescence on adherent cells. There are many works
in which doubts about the limitations in the use of antibody are
discussed [45]. The antibodies more commonly used recognize
Figure 5. Pneumospheres formation ability evaluation and CD133 expression on LC31 and EMT-LC31 cell lines. A: LC31
pneumospheres; EMT-LC31 pneumospheres; C: CD133 expression on EMT-LC31 pneumospheres.
doi:10.1371/journal.pone.0021548.g005
Table 1. % colonies formation for LC31 cell line.
N6
seeded
cells
% colonies
formation
LC31
% colonies
formation
EMT-LC31
Fold
increase p-value
1.000 0.82 15 18 0.0001
10.000 5.10 14.80 3 0.002
doi:10.1371/journal.pone.0021548.t001
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their use carries the risk of underestimated non glycosylated forms
of the antigen. Moreover, several CD133 mRNA splicing have
been identified, which would in turn give rise to protein products
not recognizable by common antibodies; finally, intrinsic limita-
tions of immunofluorescence and cytometry methodologies, which
implies antibody sensitivity, epitope damage due to routine
fixation/inclusion procedures, antigen retrieval, enzymatic steps
of cell preparation must be taken into account [47]. In this context,
we can also hypothesize that TGFb-1 treatment give rise to
conformational change of CD133 epitopes and its antibody is not
able to recognize the molecule in cytometry and immunofluores-
cence procedures. In the pneumospheres, most probably,
tridimensional structure allows the exposure of the epitopes
recognized by common antibodies. Moreover, they are not subject
to enzymatic steps that could damage cellular structure.
Although this consideration, RT-PCR and Western blot
confirm the same the stemness feature of EMT-LC31 cell line
after treatment of TGFb-1 with up-regulation both CD133 m-
RNA and CD133 protein.
Finally, to evaluate TGFb-1 effect on tumorigenic potential , we
performed both soft agar assay and tumorigenicity in vivo. TGFb-1,
in line with cancer stem cells concept, induces an increase of
colonies formation in soft agar experiments and the volume of
tumours was significantly larger than that of untreated LC31 cell
line confirming that EMT phenotype not only promoted stemness
phenotype but also the tumorigenicity. In conclusion, the cells with
EMT phenotype promoted tumorigenicity.
Therefore, the high probability that the EMT generates cells
with many of the properties of self-renewing stem cells is verified
by increased expression of Nanog, Oct4 and Sox2 , determinant
self-renewal factors and CD133 and c-Kit, main stemness markers
of CSCs in lung cancer.
In conclusion, we report that the induction of EMT by TGFb-1
treatment in a primary lung cancer cell line results in the acquisition
of mesenchymal profile and in up-regulation of the expression of
stem cell markers.
This study highlights the possibility to address a novel pharmaco-
logical approach versus EMT-phenotype cells or cancer stem-like cells
for the prevention of tumour progression and metastasis formation.
Materials and Methods
Ethics Statement
The experimental protocols have been evaluated and approved
from the ethical committee on animal use of Biogem. The
experimental project have the approval ID 10.08 and have been
communicated in May 26
th, 2008 to the Italian Minister of Health,
following the national laws concerning the protection of animal
welfare. The patient, enrolled in this study, had signed informed
consent, approved by our Internal Ethical Committee (National
Cancer Institute, Naples).
Cell Culture
A549 cell line was purchased from ATCC Cell Bank and was
cultured in RPMI1640 (Lonza, Milan, Italy) at 10% fetal bovine
serum (FBS) at 37uC, 5%CO2. LC31 cell line has been obtained in
our laboratory by a patient affected from lung squamous adenocar-
cinoma with written informed consent, approved by our Internal
Ethical Committee (National Cancer Institute, Naples) and was
cultured in IMDM (Lonza) at 10% FBS [14]. For experiments, cells
were grown to 90% confluence.
TGFb-1 treatment and Growth Curves
In order to induce EMT process, A549 and LC31 cell lines were
treated with 2 ng/ml TGFb-1 (AbCAM, Milan, Italy) for 30 and
80 days, respectively. TGFb-1 has been added twice a week in the
medium. To test the possible growth inhibition due to TGFb-1
treatment, 10,000 cells were plated in 24well plates for each cell
line and TGFb-1 untreated and treated cells were detached every
24 hours for 10 days. The number of cells for each experimental
condition was counted and represented on a linear graph. The
doubling time (DT) was determined from the growth curves by
using the formula:
DT~(t-t0)log2=(logN-logN0)
where t and t0 were the times at which the cells were counted, and
N and N0 were the cell numbers at times t and t0, respectively.
Pneumospheres assay
In order to evaluate the effect of TGFb-1 on pneumospheres
growth and formation, the LC31 cell line was plated at a density of
60,000 cells per well in six-well ultra-low attachment plates (Corning
Inc., Corning, NY, USA) in BEBM cell medium, supplemented with
BEGM [prepackaged SingleQuots containing retinoic acid, bovine
pituitary extract, insulin, hydrocortisone, transferrin, triiodotyronine,
epinephrine, human epidermal growth factor, gentamicin and
amphotericin B (all from Lonza Group Ltd., Basel, Switzerland) plus
human EGF (10 ng/ml; Sigma, Milan, Italy) and human bFGF
(10 ng/ml;Sigma,Milan,Italy). Cellswere incubated in a humidified
atmosphere at 37uCw i t h5 %C O 2. Fresh aliquots of TGFb-1, EGF
and bFGF were added twice a week. After 48–72 h of culture,
spheres were visible at inverted phase-contrast microscopy.
Figure 6. Colony efficiency analyses. A: photographs of colonies from LC31 cell line and [B] EMT-LC31 cell line; C: the colony number was
counted and the data were presented as CFU (%) respect to cell number seeded.
doi:10.1371/journal.pone.0021548.g006
EMT in Primary Lung Cancer Cell Line
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In order to evaluate the effect of TGFb-1 on both stemness and
differentiation phenotype of A549, and LC31 cells lines, 200,000
cells were stained with the following antibodies (2 mg/ml): mouse
anti-human CD90 FITC (Becton & Dickinson, Buccinasco, Milan,
Italy), mesenchymal marker, mouse anti-human CD133 PE
(Miltenyi Biotec, Calderara di Reno, Bologna, Italy), mouse anti-
human CD326 PerCP (EpCAM, Becton & Dickinson), epithelial
marker, mouse anti-human vimentin (DAKO, Milan, Italy) and
mouse anti-Cytokeratin (clone CK3-6H5, Miltenyi Biotec). The
antibodies were incubated for 30 minutes at 4uC in the dark. After
incubation, the samples were washed with PBS and analyzed by
FACSAriaII (Becton Dickinson). For vimentin and citokeratin
intracellular staining, Fix and Perm kit (Invitrogen, Milan, Italy)
was used according manufacturer’s instructions. The secondary
antibody for vimentin assay was goat anti-mouse PE conjugated
(AbCAM). All data were analysed by Diva Software.
Immunofluorescence Assay
TGFb-1 untreated and treated A549 and LC31 cells were
plated in 24 well plates and were fixed with 70% ethanol/0,1%
Triton for 30 minutes at 4uC, washed with PBS, treated with 5%
Bovine Serum Albumin for 60 minutes at room temperature and
then stained with primary antibodies at 4uC over night. The
primary antibodies used were mouse anti-human CD133/1
(Miltenyi Biotec), mouse anti-human vimentin (DAKO), anti-
human E-cadherin (DAKO) and mouse anti-human citokeratin
(DAKO). The secondary antibody, goat anti-mouse FITC
(AbCAM) diluted 1:200 in PBS, was incubated for 60 min at
4uC, and the DAPI (Sigma, Milan, Italy), used to stain the nucleus,
was incubated for 7 minutes at room temperature. The same
procedure for CD133 staining was performed on LC31 cells
grown as pneumospheres after treatment of TGFb-1. Cells were
then washed twice as described above and observed under the
fluorescence microscope (Zeiss, Milan, Italy). Isotypes and non-
probed cells were used as controls.
RT-PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen,
Milan, Italy) according to the manufacturer’s protocol. RNA
concentration and purity were determined by A260 and A260/A280
ratios, respectively. The integrity of total RNA was assessed on
standard 1% agarose/formaldehyde gels. The RNA samples were
treated with DNase I to remove residual traces of DNA. cDNA
was obtained from 1 mg of total RNA, using reverse transcriptase
(Promega Italia Srl, Milan, Italy) and random primers (Promega)
in a final volume of 20 ml. cDNAs (1 ml for each sample) were
amplified by PCR using the primer sequences as follows:
CD133: 59-TCTTGACCGACTGAGACCCAAC-39(sense) and
59-ACTTGATGGATGC ACCAAGCAC-39(antisense); OCT3/
4:5 9-ACATGTGTA AGCTGCGGCC-39 (sense) and 59-GTT-
GTGCATAGTCGCTGCTTG -39 (antisense); Nanog: 59-TTC-
AGTCTGGACACTGGCTG-39 (sense) and 59-CTCGCTGAT-
TAGGCTCCAAC-39 (antisense); SOX2:5 9-CGATGCCGA-
CAAGAAAACTT-39 (sense) and 59-CAAACTTCCTGCAAAG-
CTCC-39 (antisense); Twist:5 9-TCTCGGTCTGGAGGATG-
GAG-39(sense) and 59-GTTATCCAGCTCCAGAGTCT-39 (an-
tisense); Slug:5 9-GAGCATTTGCAGACAGGTCA-39 (sense)
and 59-CCTCATGTTTGTGCAGGAGA -39 (antisense); b-
catenin: 59-GCCGGCTATTGTAGAAGCTG-39 (sense) and 59-
GAGTCCCAAGGAGACCTTCC-39 (antisense); c-kit: 59-CC-
GGTCGATTCTAAGTTCTAC-39 (sense) and 59-GATTGGT-
GCTCTCTGAAATCTG-39 (antisense).
Thermal cycle parameters were: 95uC for 2 minutes, 35 cycles of
95uC for 30 seconds, 52–60uC (depending on the Tm of each
individual set of primers) for 1 minute and 72u for 30 seconds.
GAPDH:5 9-TGGACTCCACGACGTACTCAG-39 (sense) and
59-ACATGTTCC AATATGATTCCA-39 (antisense) was ampli-
fied as an internal control. The RT-PCR products were separated
by 2% agarose gel electrophoresis, stained with ethidium bromide,
and photographed under UV illumination. RT-PCR was per-
formed on TGFb-1 treated and untreated LC31 cell line at different
treatment times (0, 20, 50 and 80 days).
Western Blotting
Total cell lysates of TGFb-1 treated and untreated LC31 cell line
at different treatment times [0, 20, 50 and 80 days] were obtained
by lysing the cells in RIPA buffer containing 50 mM Tris-HCl,
150 mM NaCl, 1% NP-40, 0,1% SDS, 0,5% sodium deoxycholate,
2 mM sodium fluoride, 2 mM Na3VO42, 1 mM EDTA, 1 mM
EGTA and protease inhibitor cocktail. Protein concentration was
determined using bicinchoninic acid protein assay (Pierce, Rock-
ford, IL). The proteins were separated by SDS-PAGE, transferred
to nitrocellulose, blocked, and incubated with the following primary
antibodies: CD133 (AbCAM) diluted 1:500 and a-tubulin (Sigma,
Milan, Italy) diluted 1:100 that was used as loading control. The
membranewaswashedand incubatedwith the respective secondary
antibodies conjugated with peroxidase. Protein detection was done
with chemiluminescence detection system (Pierce).
Soft Agar Assay
To evaluate the clonogenicity due to TGFb-1 treatment, treated
and untreated LC31 cells, at a density of 1,000, 5,000 and 10,000
cells per well in 24-well plates were plated in soft agar , in
triplicate. The test was performed using 0.8% and 0.3% agar in
IMDM as the base and top layers, respectively.
Cells were incubated for 21 days at 37uCi nah u m i d i f i e d
atmosphere at 5% CO2 in air and 50 ml of IMDM culture medium
were added twice a week. At the end of the incubation period,
colonies were stained with nitrobluetetraziolium (NBT, Sigma,
Milan, Italy) at a concentration of 50 mg/100 ml in PBS and
counted using an inverted microscope (Nikon TS 100, Milan, Italy).
The colony efficiency was calculated as proportion of colonies per
total number of seeded cells. The data were analyzed by Image Pro
Plus software.
Nonobese diabetic (NOD)/severe combined
immunodeficiency (SCID) xenotransplantation
In order to evaluate the effect of TGFb-1 on tumorigenicity, in
vivo experiments were performed. TGFb-1 untreated and treated
LC31 cells grown as pneumospheres were subcutaneously injected
in NOD/SCID mice (Charles River, Wilmington, MA). For this
purpose, cells were harvested diluted in PBS, mixed with matrigel
and injected subcutaneously in six-week-old female NOD/SCID
mice at following serial dilutions: 1 and 5610
4; 1 and 5610
5;
1610
6 cells. After 60 days, mice were sacrificed and the tumour
tissue collected, in part fixed in buffered formalin and subsequently
analysed by immunohistochemistry and in part minced to re-
obtain the cell line. Haematoxylin and eosin staining followed by
immunohistochemical analysis were performed to analyse tumour
histology. The injection experiments were in triplicate.
Statistical analyses
The data are presented as the mean values 6 SD. Comparison
between groups were evaluated by a two-tailed student’s t test.
Values of p,0,05 were considered statistically significant.
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Figure S1 EMT-LC31 cells promoted tumour growth. A:
Hematoxylin and Eosin evaluation of the LC31 human tumour; B:
Hematoxylin and Eosin evaluation starting from EMT-LC31 cells
injected in NOD/SCID mice that resembles human original
tumour; C: Tumor growth curve showing EMT-LC31 cells
promote tumor growth in NOD/SCID mice much faster than
LC31 cells starting from 100,000 cells injected.
(TIF)
Table S1 Tumour incidence of LC31 cells versus EMT-LC31
cells injected in NOD/SCID mice in limiting dilutions.
(DOC)
Acknowledgments
The authors specially thank Dr Alessandra Trocino; librarians of the
National Cancer Institute, Naples, for providing excellent bibliographic
services and assistance; and Dr Andrea Affuso of the Animal Model Facility
(AMF), Biogem Scarl, Via Camporeale, 83031 Ariano Irpino (AV).
Author Contributions
Conceived and designed the experiments: NN VT GR GP. Performed the
experiments: RC FP VT EL RF. Analyzed the data: NN VT GR GP.
Contributed reagents/materials/analysis tools: GR ALR NM GP. Wrote
the paper: VT NN GR GP.
References
1. Clarke MF, Fuller M (2006) Stem cells and cancer: two faces of eve. Cell 124:
1111–5.
2. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355:
1253–61.
3. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours:
accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755–68.
4. Locke M, Heywood M, Fawell S, Mackenzie IC (2005) Retention of intrinsic
stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 65: 8944–50.
5. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, et al. (2011) Human
acute myelogenous leukemia stem cells are rare and heterogeneous when
assayed in NOD/SCID/IL2Rcc-deficient mice. J Clin Invest 121: 384–95.
6. Jordan CT (2004) Cancer stem cell biology: from leukemia to solid tumors. Curr
Opin Cell Biol 16: 708–12.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and
cancer stem cells. Nature 414: 105–11.
8. D’Angelo RC, Wicha MS (2010) Stem cells in normal development and cancer.
Prog Mol Biol Transl Sci 95: 113–58.
9. Dean M, Fojo T, Bates S Tumour stem cells and drug resistance. (2005) Nat Rev
Cancer 5: 275–84.
10. Steinbach D, Legrand O (2007) ABC transporters and drug resistance in
leukemia: was P-gp nothing but the first head of the Hydra? Leukemia 21:
1172–6.
11. Chuthapisith S, Eremin J, El-Sheemey M, Eremin O (2010) Breast cancer
chemoresistance: emerging importance of cancer stem cells. Surg Oncol 19:
27–32.
12. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003)
Identification of a cancer stem cell in human brain tumors. Cancer Res 63:
5821–8.
13. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al. (2005) Isolation
and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor
cell properties. Cancer Res 65: 5506–11.
14. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and
expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ
15: 504–14.
15. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, et al. (2009) The
role of CD133 in the identification and characterisation of tumour-initiating cells
in non-small-cell lung cancer. Eur J Cardiothorac Surg 36: 446–53.
16. Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development
and cancer: role of phosphatidylinositol 39 kinase/AKT pathways. Oncogene
24: 7443–54.
17. Thiery JP, Chua K, Sim WJ, Huang R (2010) Epithelial mesenchymal transition
during development in fibrosis and in the progression of carcinoma. Bull Cancer
97: 1285–95.
18. Hay ED (2005) The mesenchymal cell, its role in the embryo, and the
remarkable signaling mechanisms that create it. Dev Dyn 233: 706–20.
19. Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ, et al. (2011) Snail2 is
an essential mediator of Twist1-induced epithelial mesenchymal transition and
metastasis. Cancer Res 71: 245–54.
20. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, et al. (2001) IGF-II
induces rapid beta-catenin relocation to the nucleus during epithelium to
mesenchyme transition. Oncogene 20: 4942–50.
21. Thiery JP (2001) Role of growth factor signaling in epithelial cell plasticity
during development and in carcinogenesis. Bull Acad Natl Med 185: 1279–92.
22. Cufı ´ S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J,
et al. (2010) Metformin against TGFb-induced epithelial-to-mesenchymal
transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle
9: 4461–8.
23. Hong KO, Kim JH, Hong JS, Yoon HJ, Lee JI, et al. (2009) Inhibition of Akt
activity induces the mesenchymal-to-epithelial reverting transition with restoring
E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma
cells. J Exp Clin Cancer Res 28: 28.
24. Thiery JP (2003) Epithelial-mesenchymal transitions in development and
pathologies. Curr Opin Cell Biol 15: 740–6.
25. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, et al. (2003)
Biology of hematopoietic stem cells and progenitors: implications for clinical
application. Annu Rev Immunol 21: 759–806.
26. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell 133:
704–15.
27. Ju HK, Young SJ, Kwang-Seok E, Young IH, Hae RK, et al. (2007)
Transforming Growth Factor b1 Induces Epithelial-to-Mesenchymal Transition
of A549 Cells. J Korean Med Sci 22: 898–904.
28. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, et al. (2010) Elimination of
human lung cancer stem cells through targeting of the stem cell factor-c-kit
autocrine signaling loop. Cancer Res 70: 338–46.
29. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, et al. (2006) Hedgehog signaling
and Bmi-1 regulate self-renewal of normal and malignant human mammary
stem cells. Cancer Res 66: 6063–71.
30. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, et al. (2007) p66Shc/
Notch-3 interplay controls self-renewal and hypoxia survival in human stem/
progenitor cells of the mammary gland expanded in vitro as mammospheres.
Stem Cells 25: 807–15.
31. Wheelock MJ, Johnson KR (2003) Cadherins as modulators of cellular
phenotype. Annu Rev Cell Dev Biol 15: 740–746.
32. Chaffer CL, Weinberg RA (2011) A Perspective on Cancer Cell Metastasis.
Science 331: 1559–1564.
33. Hayashida T, Jinno H, Kitagawa Y, Kitajima M (2011) Cooperation of cancer
stem cell properties and epithelial-mesenchymal transition in the establishment
of breast cancer metastasis. J Oncol 2011: 591427.
34. Lo JF, Yu CC, Chiou SH, Huang CY, Jan CI, et al. (2010) The Epithelial-
Mesenchymal Transition Mediator S100A4 Maintains Cancer Initiating Cells in
Head and Neck Cancers. Cancer Res 17: DOI:10.1158/0008-5472.
35. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH (2011) Up-Regulation of
Sonic Hedgehog Contributes to TGF-b1-Induced Epithelial to Mesenchymal
Transition in NSCLC Cells. PLoS One 6: e16068.
36. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, et al. (2005) Epithelial
versus mesenchymal phenotype determines in vitro sensitivity and predicts
clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:
8686–98.
37. Tong M, Ding Y, Tai HH (2006) Reciprocal regulation of cyclooxygenase-2 and
15-hydroxyprostaglandin dehydrogenase expression in A549 human lung
adenocarcinoma cells. Carcinogenesis 27: 2170–9.
38. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z (2005) TGF-beta1
induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir
Res 6: 56.
39. Lu Z, Ghosh S, Wang Z, Hunter T (2003) Downregulation of caveolin-1
function by EGF leads to the loss of E-cadherin, increased transcriptional activity
of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499–515.
40. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, et al. (2008) Generation of
pluripotent stem cells from adult mouse liver and stomach cells. Science 321:
699–702.
41. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al.
(2007) Induced pluripotent stem cell lines derived from human somatic cells.
Science 318: 1917–1920.
42. Hida T, Ueda R, Sekido Y, Hibi K, Matsuda R, et al. (1994) Ectopic expression
of c-kit in small-cell lung cancer. Int J Cancer Suppl 8: 108–9.
43. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, et al. (2010) Elimination of
human lung cancer stem cells through targeting of the stem cell factor-c-kit
autocrine signaling loop. Cancer Res 70: 338–46.
44. Levina V, Marrangoni AM, De Marco R, Gorelik E, Lokshin AE (2008) Drug-
selected human lung cancer stem cells: cytokine network, tumorigenic and
metastatic properties. PLoS One 3: e3077.
EMT in Primary Lung Cancer Cell Line
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e2154845. Ferrandina G, Petrillo M, Bonanno G, Scambia G (2009) Targeting CD133
antigen in cancer. Expert Opin Ther Targets 13: 823–37.
46. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A (2008)
Expression of the ‘‘stem cell marker’’ CD133 in pancreas and pancreatic ductal
adenocarinomas. BMC Cancer 8: 1–14.
47. Bidlingmaier S, Zhu X, Liu B (2008) The utility and limitations of glycosylated
human CD133 epitopes in defining cancer stem cells. J Mol Med 86: 1025–32.
EMT in Primary Lung Cancer Cell Line
PLoS ONE | www.plosone.org 11 June 2011 | Volume 6 | Issue 6 | e21548